Discover an informative webinar that will provide profound insights into leveraging deep therapeutic expertise in oncology, alongside a clinical development paradigm that prioritizes speed, agility and strategic collaboration, to accelerate the drug development process.
This webinar will illuminate the pathway to expediting the unique drug development journey by integrating contract development and manufacturing organization (CDMO), clinical trial supplies and contract research organization (CRO) solutions through a singular partnership. A key highlight will be the presentation of groundbreaking research from the Tufts University Center for the Study of Drug Development.
This research scrutinized oncology development by modality and clinical phase in the context of a model of net financial gain to estimate the increase in expected net present value (eNPV) and a return on investment (ROI) achievable through the acceleration of drug development timelines via integrated CDMO, clinical trial supplies and CRO services.
There will be a panel discussion that will provide actionable insights into an integrated approach, demonstrating how this strategy can amplify value across all phases of development. The expert speakers will share their perspectives on current opportunities within oncology research and drug development. They will discuss how to harness the synergies between drug development, manufacturing and clinical trial strategy and execution to propel these programs.
This webinar will empower attendees to consider the potential of an accelerated clinical development approach. Do not miss this opportunity to achieve expedited market entry for oncology therapies.
Register for this webinar today to gain invaluable insights into accelerating oncology drug development through integrated CDMO, clinical trial supplies and CRO partnerships.
Speakers
Dr. Dirk Reitsma, MD, SVP, Medical Science & Strategy, PPD, the clinical research business of Thermo Fisher Scientific
Dr. Reitsma is Senior Vice President and Therapeutic Area Head of Medical Science and Strategy. He provides clinical trial design and oncology drug development guidance to clients. He has extensive experience in the application of adaptive and other Bayesian trial methods and in complex and innovative trial designs.
After joining PPD, Dirk started working groups to study implementation of platform trials, the methodology of biosimilar trials and the implementation of Teletrials. He has more than 20 years of experience in oncology clinical development at both large pharma and biotech and worked on four oncology drug approvals in multiple tumor types. He has worked at PPD for over 15 years. Dr. Reitsma holds an MD from Erasmus University Rotterdam.
Message Presenter
Joseph A. DiMasi, PhD, Director of Economic Analysis and Research Associate Professor, Tufts University
Dr. DiMasi is Director of Economic Analysis at the Tufts Center for the Study of Drug Development and Research Associate Professor at Tufts Medical School, Tufts University. He is an internationally recognized expert on the economics of the pharmaceutical industry. Dr. DiMasi serves on the editorial board of Therapeutic Innovation and Regulatory Science and has served on the editorial boards of Journal of Research in Pharmaceutical Economics and Journal of Pharmaceutical Finance, Economics & Policy.
He also has been a member of the Board of Directors for the Phase 0 / Microdosing Network. Dr. DiMasi testified before the US Congress in hearings leading up to the FDA Modernization Act of 1997 and reauthorization of the Prescription Drug User Fee Act. Dr. DiMasi’s research interests include the R&D cost of new drug development, risks in new drug development, factors that affect the length of the development and regulatory approval processes, innovation incentives for biopharmaceutical R&D and changes in the structure and performance of the pharmaceutical and biotechnology industries.
Message Presenter
Georgi Marinov, Director, Strategic Clinical Development Consulting, PPD, the clinical research business of Thermo Fisher Scientific
Bio coming soon.
Message Presenter
Hajir Mokhtari, Director, Business Operations, PPD, the clinical research business of Thermo Fisher Scientific
Bio coming soon.
Message Presenter
Nikolay Stoyanov, Senior Director, Strategic Clinical Development Consulting, PPD, the clinical research business of Thermo Fisher Scientific
Bio coming soon.
Message PresenterWho Should Attend?
This webinar will appeal to those working in the following areas or having the following job titles:
- Executive leadership: R&D/clinical development, finance/CFO and business strategy/COO
- Clinical research and development (director and up)
- Clinical operations (director and up)
- Drug development (director and up)
- Vendor/outsourcing management (senior manager and up)
What You Will Learn
Attendees will gain a comprehensive understanding of:
- Why combining CDMO, clinical trial supplies and CRO solutions through a single partnership can significantly expedite drug development
- Why the eNPV and ROI can be positively impacted by shortening drug development timelines
- The role of collaborative partnerships in fostering innovation and overcoming development hurdles
- Actionable strategies for effectively leveraging an integrated clinical development model to maximize value across all phases of drug development
Xtalks Partner
Thermo Fisher Scientific
At Thermo Fisher Scientific, we understand that developing novel therapies and moving them from discovery to patients is a complex, high-risk process. Every customer has different needs, and every newly discovered drug has a unique pathway to reach the market. As a global, full-service CDMO and CRO, we help accelerate our partners’ unique drug development journeys with Accelerator Drug Development™, 360º CDMO and CRO solutions, supporting their aspiration to get treatments to patients faster. Thermo Fisher provides industry-leading pharma services for drug development, clinical trial research, clinical trial logistics, and commercial manufacturing. We partner with customers in the pharmaceutical, biotech, and life sciences industries as their trusted CDMO and CRO to deliver medicine to patients faster. We believe that doing this successfully not only requires science, technology, and world-class expertise, but also requires a strategic partnership—bonded by key elements such as trust, communication, and collaboration. We embed these elements into every operation, interaction, and step in the drug development journey.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account